Zenith Drugs (NSE:ZENITHDRUG) Interest Expense: ₹-56 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
36 GF Score
Price ₹48.95
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Interest Expense?

Zenith Drugs NSE:ZENITHDRUG -2.88% 36 Interest Expense is ₹-56 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 36/100. The stock has 8 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zenith Drugs's interest expense for the six months ended in Mar. 2026 was ₹ -31 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zenith Drugs's Operating Income for the six months ended in Mar. 2026 was ₹ 29 Mil. Zenith Drugs's Interest Expense for the six months ended in Mar. 2026 was ₹ -31 Mil. Zenith Drugs's Interest Coverage for the quarter that ended in Mar. 2026 was 0.96. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zenith Drugs  (NSE:ZENITHDRUG) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zenith Drugs's Interest Expense for the six months ended in Mar. 2026 was ₹-31 Mil. Its Operating Income for the six months ended in Mar. 2026 was ₹29 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Mar. 2026 was ₹201 Mil.

Zenith Drugs's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*29.417/-30.766
=0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Zenith Drugs Ltd interest coverage is 1.09, which is low.

Zenith Drugs Interest Expense Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Interest Expense Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial -19.47 -11.48 -20.01 -37.11 -56.11

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only -6.15 -12.41 -24.70 -25.35 -30.77
NSE:ZENITHDRUG
36GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹-56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-56 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Interest Expense of ₹-56 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zenith Drugs and its competitors.
Is Zenith Drugs' Interest Expense too high?
Zenith Drugs' current Interest Expense is ₹-56 Mil. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Interest Expense compare to ZTS and UTHR?
Zenith Drugs' Interest Expense of ₹-56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zenith Drugs and its competitors. Zenith Drugs's current Interest Expense is ₹-56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Interest Expense of ₹-56 Mil. The current Interest Expense is ₹-56 Mil. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Interest Expense is ₹-56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score

Get the complete analysis for NSE:ZENITHDRUG

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹48.95
Price